Semaglutide's method of action: what it actually does inside your body

The misconception worth correcting first: semaglutide is not simply a 'stomach-emptying drug'

The most persistent misunderstanding about semaglutide's method of action is that it works primarily by slowing the passage of food through the stomach. That part is real, but it explains only a fraction of what is happening. The drug acts on GLP-1 receptors in multiple tissues simultaneously, and the effects on the central nervous system are at least as important as anything going on in the gut.

GLP-1 (glucagon-like peptide-1) is released from specialised cells in your small intestine when food arrives there. Its natural job is to signal fullness, prompt the pancreas to release insulin in a glucose-dependent way, and reduce the stomach's rate of emptying. Semaglutide is a synthetic analogue of this hormone, engineered to bind the same receptor but to last far longer in circulation than the natural version, which breaks down within minutes. Because of that extended presence, the receptor activation continues steadily for days.

The brain component matters a great deal. GLP-1 receptors sit in the hypothalamus and brainstem, areas involved in hunger regulation and reward signalling around food. Activation there reduces the drive to eat between meals and can change how food looks and smells to some people, a phenomenon patients sometimes describe as food feeling less compelling. If you want to understand the full picture of how semaglutide works across all these tissues at once, the central and peripheral mechanisms together are explained in detail, because neither alone tells the whole story.

What the weekly dosing schedule reflects about how semaglutide behaves

Understanding the Wegovy method of action, including why a single injection sustains its effects across seven days, starts with appreciating how differently semaglutide behaves compared with the natural hormone it mimics. Natural GLP-1 has a half-life of around two minutes in the bloodstream. Semaglutide is modified at two points in its amino-acid sequence and has a C18 fatty-acid chain attached, which allows it to bind to albumin (a protein that circulates in the blood) and hitch a ride rather than being cleared immediately. The result is a half-life of roughly one week, which maps neatly onto the once-weekly injection schedule.

This is worth knowing because it has practical implications. The medicine takes several weeks to build to steady-state concentrations in the body, which is one reason results in clinical trials are measured across months rather than weeks. It also means that if a dose is delayed by a day or two, the pharmacological effect does not vanish overnight. Your prescriber and the patient information leaflet will give you the guidance specific to your treatment if a dose is ever missed, the NHS medicines information for tirzepatide and semaglutide covers this in straightforward terms.

The dose escalation schedule (starting at 0.25 mg and moving upward toward the 2.4 mg maintenance dose) is not primarily about building efficacy; it is about allowing the gut to adjust gradually so that nausea and other gastrointestinal effects are manageable. Titration is a clinical process guided by your prescriber, not something to rush.

You can look up the full prescribing information for semaglutide (Wegovy) on the Electronic Medicines Compendium (eMC), which holds the Summary of Product Characteristics, the definitive technical document for the medicine.

How the mechanism translates into clinical outcomes

Because semaglutide acts on appetite, reward signalling and digestion simultaneously, the weight reduction seen in clinical trials is not simply down to eating less at mealtimes. People tend to snack less, feel satisfied sooner, and experience fewer cravings, all consistent with the central receptor activity described above.

The phase 3 STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% at 68 weeks in adults treated with semaglutide 2.4 mg alongside lifestyle changes. That figure reflects the drug working through all its mechanisms together over an extended period, not a sharp early drop but a sustained trajectory. The timeline of when the effects become noticeable is a related question worth reading if you want to set realistic expectations from the start.

A single-pathway GLP-1 agonist like semaglutide differs mechanistically from tirzepatide, which additionally activates GIP receptors. Both are licensed in the UK for weight management. If you are considering which might suit your situation, the weight-loss treatment overview is a good starting point for comparing how the two approaches differ. For a closer look at the receptor biology behind how the drug works, the page covering semaglutide action examines the science in more detail.

Side effects as a window into the mechanism

The commonest side effects of semaglutide (nausea, loose stools, constipation, reflux, burping) are direct consequences of slowed gastric emptying and altered gut motility. Knowing this is practically useful, not just academically interesting. If you experience nausea after starting or after a dose increase, it is usually the gut adjusting to a pace of digestion it is not used to. Symptoms are typically most noticeable in the first week or two at a new dose and tend to ease as the body acclimatises.

One quick habit that can help: before your first injection at each new dose, check whether you have eaten a large or fatty meal in the preceding hour or two. Heavy meals slow absorption and can intensify nausea when combined with an already-slowing gut. That one-minute check before dosing is something our prescribers often mention to patients starting treatment.

More rarely, GLP-1 medicines can affect the gallbladder (rapid weight loss independently raises gallstone risk) and, in uncommon cases, the pancreas. The NHS medicines page for semaglutide lists which symptoms should prompt you to seek medical advice promptly. Severe, persistent abdominal pain that radiates to the back is the one that warrants urgent attention. These are prescription-only treatments assessed and monitored by a prescriber for good reason. If you have questions about how semaglutide might interact with your own health picture, a free consultation with our prescribers is the right place to start.